Serum half-life is an essential pharmacokinetic attribute of therapeutic antibodies and thus, tools to accurately predict their clearance can advance development of novel therapies. An important determinant of the half-life of immunoglobulins is binding to neonatal Fc receptor (FcRn).
FcRn chromatography is a simple and robust method to characterize the binding of antibodies to FcRn, overcoming limitations of technologies like surface plasmon resonance (SPR) immunoassays.
The FcRn Affinity Column Gen2 offers a versatile method to standardize and speed up the development and quality control of the optimal structures of monoclonal antibodies for therapeutic use. The FcRn IgG Control enables easy and reliable control of the function of the column.